Invega Sustenna, also known by its generic name paliperidone palmitate extended-release injectable suspension, is a long-acting antipsychotic medication developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1][2]. It is used for the treatment of schizophrenia and schizoaffective disorder in adults [1][3].
How does Invega Sustenna work?
Invega Sustenna is an atypical antipsychotic that works by affecting dopamine and serotonin neurotransmitter systems in the brain [1]. Paliperidone, the active ingredient, is the active metabolite of risperidone, another antipsychotic drug [2]. The extended-release formulation allows for infrequent dosing, typically administered monthly, to maintain therapeutic levels of the medication [1][3].
When did Invega Sustenna receive approval?
Invega Sustenna was approved by the U.S. Food and Drug Administration (FDA) in 2009 [4].
What is the typical dosing and administration of Invega Sustenna?
Invega Sustenna is administered as an intramuscular injection [1]. Dosing regimens typically involve initiation with a loading dose followed by monthly maintenance injections. The specific dosage and schedule are determined by a healthcare professional based on the patient's condition and response [3].
What are the potential side effects of Invega Sustenna?
Common side effects associated with Invega Sustenna can include injection site reactions, headache, weight gain, dizziness, and akathisia (a feeling of inner restlessness) [3]. More serious, though less common, side effects may involve movement disorders like tardive dyskinesia, metabolic changes, and cardiac issues [1][3].
What is the patent status for Invega Sustenna?
Information regarding specific patent expiry dates for Invega Sustenna is available through resources like DrugPatentWatch.com [5]. Patent protection for pharmaceuticals is crucial for manufacturers, influencing market exclusivity and the potential for generic competition.
Are there other long-acting injectable antipsychotics available?
Yes, several other long-acting injectable antipsychotic medications are on the market, including some that are also based on paliperidone, such as Invega Trinza and Invega Hafyera, which offer longer dosing intervals [6]. Other antipsychotics with long-acting injectable formulations from different drug classes are also available [7].
Who manufactures Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals [1].
---
Sources
1. https://www.janssen.com/
2. https://www.drugbank.ca/drugs/Paliperidone
3. https://www.fda.gov/drugs
4. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022265
5. https://drugpatentwatch.com/
6. https://www.invegasustenna.com/
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924015/